Myriad Genetics

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Myriad Genetics ( MYGN) is a molecular diagnostic company. Myriad Genetics is focused on developing and marketing predictive medicine, personalized medicine and prognostic medicine tests. It performs all of the molecular diagnostic testing and analysis for its tests in its own reference laboratory. This stock is trading up 5% at $23.94 in recent trading.

Today's Volume: 1.3 million

Average Volume: 664,112

Volume % Change: 284%

Shares of MYGN are ripping higher today after the Supreme Court made a decision to remand back to the Court of Appeals Federal Circuit a patent case between ACLU and Myriad Genetics.

From a technical perspective, MYGN are rising sharply today back above its 50-day moving average of $23.59 on heavy volume.

Traders should now look for more upside and long biased trades if MYGN can take out some near-term overhead resistance around $24.50 with high-volume. Look for volume on that move that's near or well above 664,112 shares. If we get that action today or soon, then look for MYGN to re-test its recent high of $25.75.

Myriad shows up on a list of 4 Upgraded, Undervalued Stocks.

If you liked this article you might like

Biotech Movers: Jazz Shares Lower Amid Notes Offering

Biotech Movers: Myriad Genetics, Spectrum Pharmaceuticals, Array BioPharma

Bullish and Bearish Reversals in the Market

Biotech Premarket Movers: Sage Therapeutics, Immunomedics, Myriad Genetics

Gilead Sciences Leads Biotech Movers -- Plus Jim Cramer's Comments